Beam Therapeutics — Third Quarter 2026 Earnings Summary

Beam Therapeutics reported a net loss of $134.4 million for the third quarter of 2026, with cash, cash equivalents, and marketable securities totaling $1.0 billion as of September 30, 2026. The company expects to complete dosing in the pivotal cohort of its BEAM-302 trial for alpha-1 antitrypsin deficiency in the first half of 2027 and anticipates submitting a Biologics License Application for risto-cel in sickle cell disease by the end of 2026. Updated clinical data presented at the European Respiratory Society Congress demonstrated durable increases in functional AAT and reductions in mutant Z-AAT for BEAM-302, while initial data for BEAM-301 in glycogen storage disease type Ia showed dose-dependent improvements in fasting hypoglycemia. Beam plans to initiate dosing for its BEAM-304 program in phenylketonuria in early 2027 and appointed Eric Foster as chief commercial officer to lead commercial strategy as programs advance toward potential launches.